Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jamal, Rahima
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Recruiting	2/3	420	Europe, Canada, US, RoW	IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome	IDEAYA Biosciences	Metastatic Uveal Melanoma	01/27	01/28
NCT04836195: Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma	Recruiting	1	60	Canada	PCLX-001	Pacylex Pharmaceuticals, Ozmosis Research Inc.	B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor	10/24	12/24
Villier, Arnaud
No trials found